A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

EP: 6.Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System ...

Side effects of biologic drugs may include: respiratory infections headaches flu-like symptoms swelling, itching, or a rash at the injection site urinary tract infection Two types of biologic ...

Intravitreal injections of anti-VEGF agents have become an important tool in the management of some of the most common retinal and choroidal neovascular diseases. Adverse effects are uncommon ...